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Abstract Defects in mitochondrial oxidative metabolism, in
particular decreased activity of cytochrome c oxidase, have been
demonstrated in Alzheimer’s disease, and after the expression of
the amyloid precursor protein (APP) in cultured cells, suggesting
that mitochondria might be involved in L-amyloid toxicity.
Recent evidence suggests that the proteolysis of APP to generate
L-amyloid is at least in part intracellular, preceding the
deposition of extracellular fibrils. We have therefore investigated
the effect of incubation of isolated rat brain mitochondria with
the L-amyloid fragment 25^35 (100 WM) on the activities of the
mitochondrial respiratory chain complexes I, II^III, IV (cyto-
chrome c oxidase) and citrate synthase. The peptide caused a
rapid, dose-dependent decrease in the activity of complex IV,
while it had no effect on the activities on any of the other
enzymes tested. The reverse sequence peptide (35^25) had no
effect on any of the activities measured. We conclude that
inhibition of mitochondrial complex IV might be a contributing
factor to the pathogenesis of Alzheimer’s disease.
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1. Introduction
Deposition of amyloid L peptide (AL) in the brain is a
characteristic hallmark of the pathology of Alzheimer’s dis-
ease (AD) and some other neurodegenerative disorders. It is a
constituent of senile plaques, in the form of aggregated in-
soluble ¢brils surrounded by dystrophic neurites and activated
microglia and astrocytes [1]. AL has been demonstrated to be
neurotoxic to primary cultures of neurones and several neuro-
nal cell lines, but only when forming L sheets which aggregate
into ¢brils [2]. The mechanism of AL toxicity is not known,
although a potentiation of glutamate toxicity and disruption
of calcium homeostasis have been observed in cultured neuro-
nes [3]. It has been assumed that AL produces its e¡ects at the
level of the plasma membrane, since amyloid deposits are
classically extracellular. However, growing evidence is show-
ing that the aberrant, amyloidogenic processing of the amy-
loid precursor protein (APP) also takes place intracellularly in
neurones [4], where it may encounter favourable conditions
for aggregation (i.e. high local concentration, lower pH, small
amounts of free radicals), and form ¢brils which would be
deposited, without being degraded, after the cell’s death [5].
An intracellular AL-binding protein localised in the endoplas-
mic reticulum and mitochondria and mediating AL toxicity
has been identi¢ed [6,7].
Incubation with aggregated AL also decreases the cellular
redox activity in cultures of primary neurones, astrocytes,
HeLa and PC12 cells, as measured by the chemical reduction
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bro-
mide (MTT) [8^10]. The site of reduction of this dye seems
to be at least in part mitochondrial, at the level of succinate
dehydrogenase, although other NADH/NADPH-linked proc-
esses might be involved [11]. The decrease in MTT reduction
is detectable before the cells show other signs of degeneration,
as measured by lactate dehydrogenase release or decreased
[3H]thymidine incorporation [10], suggesting a possible direct
e¡ect on mitochondria which may initiate the neurotoxic cas-
cade.
Defects in mitochondrial oxidative metabolism have been
demonstrated in AD, including decreased activity of mito-
chondrial complex IV in post-mortem brain, particularly in
the cortical areas most a¡ected by the disease [12,13] ; this is
unlikely to be due to a loss of mitochondria, since complex IV
activity was decreased in AD samples even when expressed in
relation to the activity of the mitochondrial marker citrate
synthase [14], and when measured in isolated mitochondria
[15]. Mitochondria are one of the major cellular sources of
superoxide, and the production of superoxide increases when
the £ow of reducing equivalents through complex IV is inhib-
ited [16]. Lipid peroxidation and free radical damage have
been found to be increased in the cerebral cortex in AD
[17], as well during normal aging and in Down’s syndrome,
which are also accompanied by the deposition of amyloid
plaques [18].
The APP gene has been overexpressed in cultured human
muscle cells, causing mitochondrial structural abnormalities
and decreased complex IV activity [19]. AL has been shown
to initiate lipid peroxidation in synaptosomal membranes [20],
increase oxidative stress in cultured neurones [21] and lower
synaptosomal ATP levels [22]. In some studies, antioxidants
such as vitamin E, propyl gallate and nordihydroguaiaretic
acid were shown to protect cultured neurones from AL tox-
icity [23,24], although another group have failed to con¢rm
these ¢ndings [25]. Disruption of energy metabolism and gen-
eration of reactive oxygen species favour the aberrant metab-
olism of APP to generate amyloidogenic fragments [26] and
promote aggregation of AL [27]. AL and superoxide therefore
seem to potentiate the formation of each other and result in
cellular toxicity.
The fragment of the AL peptide consisting of the sequence
of amino acids 25^35 has also been shown to have the neuro-
toxic properties of the full-length sequence, and it has the
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experimental advantage of rapidly aggregating upon solubili-
sation in aqueous bu¡ers [28]. In order to test the hypothesis
that amyloid peptides might damage cells by impairing mito-
chondrial respiratory chain function, we have studied the ef-
fects of the 25^35 fragment on isolated mitochondria from rat
brain, and measured the activities of complex I, complexes II^
III and complex IV. Citrate synthase activity was also meas-
ured as a marker of mitochondrial mass. Two types of control
conditions were used: mitochondria were incubated in the
presence of a peptide composed of the same amino acids as
the amyloid fragment 25^35 but in the reverse sequence (35^
25), or with the same volume of water, the vehicle in which
the peptides were dissolved.
2. Materials and methods
All chemicals and enzymes used were supplied by The Sigma Chem-
ical Company (Poole, UK), BDH (Dagenham, UK) or Boehringer
Mannheim (Lewes, UK). CoQ1 was the kind gift of the Eisai Chem-
ical Company (Tokyo, Japan).
Non-synaptic brain mitochondria were isolated from adult male
Wistar rats (BpK, Hull, UK; approx. 250^300 g), using the method
of Lai and Clark [29]. The puri¢ed mitochondrial fraction was resus-
pended in isolation medium (320 mM sucrose, 1 mM potassium
EDTA, 10 mM Tris-HCl, pH 7.4) at 4‡C at a protein concentration
of V1 mg/ml. The preparations were freeze-thawed three times before
the assays to allow rapid access of the substrates and cofactors to the
enzymes.
The amyloid peptide fragment 25^35 and the reverse sequence pep-
tide 35^25 were dissolved in deionised double distilled water at the
concentration of 1 mM and kept in aliquots at 370‡C.
A hundred microlitres of the mitochondria were incubated with
10 Wl of vehicle, or with the same volume of peptide solution to
give the desired ¢nal concentration. Incubations were carried out at
20‡C for the indicated times, and the samples immediately added to a
cuvette for the enzyme activity measurement.
The activities of mitochondrial complex I [30], complex II^III [31],
complex IV [32] and citrate synthase [33] were measured spectropho-
tometrically at 30‡C.
Mitochondrial protein concentration was measured using the meth-
od of Lowry et al. [34], with bovine serum albumin used as a stand-
ard.
One-way ANOVA was used for statistical analysis. Where a signi¢-
cant di¡erence was detected, the Tukey test for multiple comparisons
was applied. Correlation was evaluated by calculating the correlation
coe⁄cient (r), and the signi¢cance was tested using published tables of
critical values of the r distribution.
3. Results
Fig. 1 shows the activities of mitochondrial complex I, com-
plexes II^III, complex IV and citrate synthase after 5 min
incubation with 100 WM peptides. There was no signi¢cant
di¡erence between the speci¢c activities in the three groups
for complex I, complex II^III or citrate synthase. However,
there was a signi¢cant di¡erence in the activity of complex IV
(P6 0.001). The two control groups were not di¡erent from
each other, whereas the group incubated with the 25^35 pep-
tide was signi¢cantly lower (337%, P6 0.05). Similar results
were obtained when activities were expressed in relation to the
activity of citrate synthase, taken as a marker of the mito-
chondrial matrix (335.5%, P6 0.005).
Fig. 2 shows the titration of the activity of complex IV with
various concentrations of the 25^35 peptide. The activity of
the enzyme is inhibited by the peptide in a dose-dependent
way. The graph shows a signi¢cant linear correlation between
the logarithm of peptide concentration and activity
Fig. 1. Enzyme activities of respiratory chain complexes I (A), II^III (B), IV (C) and citrate synthase (D) in mitochondria incubated for 5 min
in the presence of water (vehicle), 100 WM reverse sequence peptide (35^25) or 100 WM amyloid fragment 25^35 (25^35). Data are the means
þ S.E.M. of n = 7^8 experiments. Enzyme activities are shown as speci¢c activity (hatched column; expressed in nmol min31 mg protein31, ex-
cept complex IV activity, which is expressed in k min31 mg protein31) and as ratio to citrate synthase activity (dotted column). *P6 0.05 vs
vehicle; #P6 0.05 vs 35^25, Tukey test.
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(r = 0.9973; P6 0.001). The calculated apparent Ki is approx-
imately 100 mM.
Fig. 3 shows the time course of complex IV activity inhi-
bition by incubation with 100 WM amyloid fragment 25^35.
The speci¢c activity decreased in a biphasic manner, very
rapidly at ¢rst, and subsequently at a much slower rate over
the following 30 min of incubation.
A hundred micromolar 25^35 peptide did not a¡ect ferro-
cytochrome c autooxidation or ferricytochrome c autoreduc-
tion in the absence of mitochondrial sample (not shown).
4. Discussion
We performed a short-term incubation of isolated mito-
chondria in the presence of the amyloid fragment 25^35
with the rationale that if a direct e¡ect was taking place in-
volving, as has been suggested, perturbation of lipid mem-
branes [35], it would be very rapid. The concentration of
peptide we initially used (100 WM) may appear high compared
to reported experiments on cultured cells where the peptides
were present for hours or days, however: (1) although the
aggregation of the 25^35 peptide is reported to be immediate
in solution, we sought to optimise the conditions for aggre-
gation (a prerequisite for toxicity), which increases with pep-
tide concentration; (2) we aimed at emulating the scenario in
which the amyloid generated intracellularly may be locally
very concentrated. The data show that the 25^35 peptide
can speci¢cally decrease mitochondrial complex IV activity
by acting directly on isolated mitochondria. This e¡ect was
observed also at lower concentrations of peptide, in a dose-
dependent manner, and took place very rapidly (less than 1
min).
Complex IV activity is particularly sensitive to the £uidity
and composition of the membrane lipid environment; in par-
ticular bound cardiolipin, phosphatidylcholine and phospha-
tidylethanolamine are essential for activity [36]. It has been
shown that these lipids can undergo peroxidation, causing loss
of complex IV activity [37,38]. Aggregates of AL interact with
lipid membranes [35] perturbing their structure. Intracellular
AL may modify mitochondrial membranes, and inhibit com-
plex IV, thereby increasing the production of superoxide at
complexes I^III [16]. This would induce lipid peroxidation
which further damages the activity of complex IV, and pro-
mote the aggregation of more AL [27]. Increased lipid perox-
idation and decreased complex IV activity are found in brain
tissue from AD patients [12,13,17]. Mitochondrial dysfunction
would also impair calcium homeostasis and generally reduce
the availability of energy for cellular functions, such as gluta-
mate uptake: this could also explain the increased sensitivity
to excitatory amino acid toxicity in cells treated with the pep-
tide [3].
In summary, these results support the possibility of a cen-
tral role of mitochondria in the neurodegenerative process
induced by the amyloid peptide, by a direct inhibition of the
activity of mitochondrial complex IV.
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